SHUKRAPHAR54.00

Shukra Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Revenue from Operations58.874.6
Other Income1.22.8
Total Income60.077.4
Expenses
+ Purchases of Stock-in-Trade0.20.2
+ Changes in Inventories-0.30.7
+ Employee Benefit Expense4.95.6
+ Finance Costs0.30.3
+ Depreciation & Amortisation1.82.1
+ Other Expenses3.35.0
EBITDA5.419.4
EBIT3.517.4
Profit
PBT before Exceptional Items4.419.9
Pretax Income4.419.9
+ Current Tax0.21.4
+ Deferred Tax0.0-0.0
Tax Expense0.01.3
Net Income4.418.5
Total Comprehensive Income4.418.5
Per Share
Basic EPS26.2123.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit59.073.7
Gross Margin %100.2998.82
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)4.419.9
Net Income Adj (tax-effected)4.418.5
EPS Adj26.2123.00
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.